The overarching mission of the OHSU Department of Cell, Developmental & Cancer Biology is to advance the understanding of problems relevant to human health and disease. To accomplish this mission, research groups in the department have historically focused on questions regarding cell structure, organelles, life cycle, differentiation, and regulated communication between cells and extracellular signals and cues. An ultimate application of knowledge gained from these studies has been to understand important cell physiologic processes that effect human biology. These issues directly link to problems of interest to developmental biologists, including molecular and cellular mechanisms regulating tissue morphogenesis, tissue polarity and patterning. Read full welcome message here.
Welcoming new members during modified operations
Many new faces have joined us since OHSU's modified operations began in March 2020. We have created a page where you will find a photo and bio for faculty, staff, and students who have joined during this time. Visit the page here.
At AACR's Tumor Immunology and Immunotherapy event in November, CDCB research presented their research.
News and recognitions
The Malhotra Lab published, "Novel Aza-podophyllotoxin derivative induces oxidative phosphorylation and cell death via AMPK activation in triple-negative breast cancer" in the British Journal of Cancer. Read the paper here.
The Mills Lab published has two recent publications:
"Large-Scale Characterization of Drug Responses of Clinically Relevant Proteins in Cancer Cell Lines" in Cancer Cell. Read the paper here.
"Differential expression of MAGEA6 toggles autophagy to promote pancreatic cancer progression" in Elife. Read the paper here.
CDCB's Dr. Evan Lind and members of the Lind lab recently published, "Reversible suppression of T cell function in the bone marrow microenvironment of acute myeloid leukemia," in the Proceedings of the National Academy of Sciences of the United States of America. The paper has also been named the "Paper of the Month" by the OHSU School of Medicine. Read the paper here.
A group of OHSU researchers, including CDCB's Dr. Amy Moran, recently published, "A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide alone," in the Journal of ImmunoTherapy of Cancer. Read the paper here.
The Schedin lab's Dr. Sonali Jindal published, "Comparison of Mortality Among Participants ofWomen’s Health Initiative Trials With Screening-Detected Breast Cancers vs Interval Breast Cancers," in JAMA Network Open. Read the paper here.
The Schedin lab's Dr. Elizabeth Mitchell published, "Loss of myoepithelial calponin‐1 characterizes high‐risk ductal carcinoma in situ cases, which are further stratified by T cell composition, in Molecular Carcinogenesis." Read the paper here.
The Walker Lab published, NKTR-214 immunotherapy synergizes with radiotherapy to stimulate systemic CD8+ T cell responses capable of curing multi-focal cancer, in the Journal for ImmunoTherapy of Cancer which was featured in the spotlight of ACIR's June 11 2020 Weekly Digest.
The Enns Lab has three recent publications:
- "The Ectodomain of Matriptase-2 Plays an Important Non-Proteolytic Role in Suppressing Hepcidin Expression in Mice" in Blood. Read the paper here.
"Insights into basic science: what basic science can teach us about iron homeostasis in trauma patients" in Current Opinion in Anesthesiology. Read the review here.
"Extrahepatic deficiency of transferrin receptor 2 is associated with increased erythropoiesis independent of iron overload" in the Journal of Biological Chemistry. Read the paper here.
Congratulations to Samuel Tsang, Ph.D. (Research Assistant Professor, Mills lab) and Aurora Blucher, Ph.D. (Postdoctoral Scholar, Mills lab) who are both OHSU Center for Women’s Health Circle of Giving 2020 awardees.
Congratulations to Amy Moran, Ph.D. whose invited presentation at the Immuno-Oncology Young Investigator's Forum won first place in the research scientist category. Her talk focused on work revealing how androgen receptor activity is a critical determinant of checkpoint blockade efficacy.
Congratulations to the OHSU Knight Cancer Institute's Center for Experimental Therapeutics, directed by Sanjay Malhtora, Ph.D., which has been awarded one of eleven grants from the Indo-U.S. Science and Technology Forum (IUSSTF) to form a virtual network for COVID-19 research.
Congratulations to Michelle Ozaki, graduate student in the Schedin Lab, who recently received the ACRS Scholar Award and was one of three OHSU students to receive a 2020 National Science Foundation Graduate Research Fellowship.
Congratulations to Philip Copenhaver, Ph.D. who was recently awarded a five-year RF1 grant to investigate how signaling by the Amyloid Precursor Protein (APP) controls neuronal guidance within the developing nervous system.
Congratulations to Mara Sherman, Ph.D. who is the recipient of a Pew Scholar award. As part of the 2020 class of the Pew-Stewart Scholars Program for Cancer Research, Dr. Sherman will receive a four-year grant to advance innovative research into the development, diagnosis, and treatment of cancer. Learn more here.
Congratulations to Adrian Baris (Anand Lab) and Reed Hawkins (Moran Lab), two CDCB students who have each received a training grant from the NIH Ruth L Kirschstein T32 Program in Enhanced Research Training (PERT), and will spend one year in intensive training that emphasizes the competencies they will need to develop a successful career in biomedical research.
The OHSU School of Medicine's Office of Graduate Studies has released the 2020 report of career outcomes for its 518 PhD recipients, including Cancer Biology and Cell & Developmental Biology program graduates. Read the report here.
CDCB's Philip Copenhaver, Ph.D. and his fourth-year M.D. mentee, Eric Nomura, were featured in OHSU News article "Scholarly projects showcase student creativity from the heart", which explores how the pair developed Eric's capstone project.
View all CDCB news and recognitions.
CDCB is excited to welcome Sanjay Malhotra, Ph.D. Dr. Malhotra is joining us as a professor and will co-lead the Knight Cancer Institute's new center, the Center for Experimental Therapeutics. Dr. Malhotra's background is in chemical biology and drug development with a strong expertise in medicinal chemistry, including small molecule synthesis. Visit the Malhotra lab website to learn more. Welcome, Dr. Malhotra!
CDCB is pleased to announce that Jonathan Brody, Ph.D., will be joining us as a joint faculty member as a professor with the Department of Surgery and Cell, Developmental & Cancer Biology. The main focus of Dr. Brody's laboratory is to understand the molecular aspects of pancreatic cancer cells and find novel therapeutic strategies for pancreatic cancer patients. Visit the Brody lab website to learn more. Welcome, Dr. Brody!
CDCB would like to welcome Robert Eil, M.D., who will be joining us as a joint faculty member with the Department of Surgery. Dr. Eil is an assistant professor as well as the Knight Cancer Institute's Director of Solid Tumor Surgical Immuno-oncology. Dr. Eil is a surgeon-scientist with a long-term goal of applying T cell-based immunotherapy to cancers involving the liver. Visit the Eil lab website to learn more. Welcome, Dr. Eil!
CDCB is pleased to announce that Megan Ruhland, Ph.D. will be joining the department as an Assistant Professor with a focus on tumor immunology. She joins us now from the University of California, San Francisco where she was a CRI Irvington Postdoctoral Fellow. Visit the Ruhland lab website to learn more. Welcome, Dr. Ruhland!